AU737086B2 - Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome - Google Patents

Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome Download PDF

Info

Publication number
AU737086B2
AU737086B2 AU89237/98A AU8923798A AU737086B2 AU 737086 B2 AU737086 B2 AU 737086B2 AU 89237/98 A AU89237/98 A AU 89237/98A AU 8923798 A AU8923798 A AU 8923798A AU 737086 B2 AU737086 B2 AU 737086B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
administered
formula
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU89237/98A
Other languages
English (en)
Other versions
AU8923798A (en
Inventor
Martin B. Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orphan Medical Inc
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of AU8923798A publication Critical patent/AU8923798A/en
Application granted granted Critical
Publication of AU737086B2 publication Critical patent/AU737086B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU89237/98A 1997-08-29 1998-08-27 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome Ceased AU737086B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/920,979 US5990162A (en) 1997-08-29 1997-08-29 Method for treatment of fibromyalgia and chronic fatigue syndrome
US08/920979 1997-08-29
PCT/US1998/017818 WO1999009972A1 (en) 1997-08-29 1998-08-27 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome

Publications (2)

Publication Number Publication Date
AU8923798A AU8923798A (en) 1999-03-16
AU737086B2 true AU737086B2 (en) 2001-08-09

Family

ID=25444733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU89237/98A Ceased AU737086B2 (en) 1997-08-29 1998-08-27 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome

Country Status (14)

Country Link
US (1) US5990162A (cs)
EP (1) EP1017381B1 (cs)
JP (1) JP3660587B2 (cs)
AT (1) ATE289508T1 (cs)
AU (1) AU737086B2 (cs)
CA (1) CA2301723C (cs)
CZ (1) CZ295248B6 (cs)
DE (1) DE69829112T2 (cs)
ES (1) ES2235355T3 (cs)
IL (2) IL134669A0 (cs)
NO (1) NO326479B1 (cs)
NZ (1) NZ502983A (cs)
PT (1) PT1017381E (cs)
WO (1) WO1999009972A1 (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316309A1 (en) * 1998-12-23 2003-06-04 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
CA2355293C (en) * 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
JP5031144B2 (ja) 1999-03-25 2012-09-19 メタボリックス，インコーポレイテッド ポリヒドロキシアルカノエートポリマーの医療デバイスおよび医療適用
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
WO2001019361A2 (en) * 1999-09-14 2001-03-22 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
WO2009097526A2 (en) * 2008-01-30 2009-08-06 Great Lakes Biosciences, Llc Brain-related chronic pain disorder treatment method and apparatus
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
ES2527857T3 (es) 2003-05-08 2015-01-30 Tepha, Inc. Tejidos y fibras médicas de polihidroxialcanoato
PT1778305E (pt) 2004-08-03 2010-07-27 Tepha Inc Suturas de poli-hidroxialcanoato que n†o se enrolam
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ｇｈｂ 조성물
KR20070085838A (ko) * 2004-11-10 2007-08-27 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 운동 장애의 치료 방법
US20080293698A1 (en) * 2005-05-16 2008-11-27 Joseph Johnson Methods and Compositions for Treating Arg
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
CN102099033B (zh) * 2008-05-16 2012-10-24 阿克西斯股份有限公司 用于治疗纤维肌痛症的药物组合物
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
CA2732479A1 (en) * 2011-02-14 2012-08-14 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
KR101976218B1 (ko) * 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체
EP2961738B1 (en) 2012-11-14 2019-12-25 CJ CheilJedang Corporation Production of salts of 4-hydroxybutyrate using biobased raw materials
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
EP3180040B1 (en) 2014-08-15 2020-05-13 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
WO2016094669A1 (en) 2014-12-11 2016-06-16 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
WO2016102407A1 (en) 2014-12-22 2016-06-30 Sanofi-Aventis Deutschland Gmbh Drug delivery device with electromagnetic drive unit
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
EP4228620A2 (en) 2020-10-16 2023-08-23 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド １晩１回の低ナトリウムオキシベート組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561408A1 (en) * 1992-03-18 1993-09-22 Kaken Pharmaceutical Co., Ltd. Agent for treatment of chronic fatigue syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561408A1 (en) * 1992-03-18 1993-09-22 Kaken Pharmaceutical Co., Ltd. Agent for treatment of chronic fatigue syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. MAMELAK ET AL, SLEEP, 9(1), PP. 285-289 *

Also Published As

Publication number Publication date
IL134669A (en) 2006-08-20
DE69829112T2 (de) 2005-08-25
CA2301723A1 (en) 1999-03-04
AU8923798A (en) 1999-03-16
CA2301723C (en) 2008-02-19
IL134669A0 (en) 2001-04-30
ATE289508T1 (de) 2005-03-15
WO1999009972A1 (en) 1999-03-04
CZ295248B6 (cs) 2005-06-15
JP2001513552A (ja) 2001-09-04
DE69829112D1 (de) 2005-03-31
EP1017381B1 (en) 2005-02-23
EP1017381A1 (en) 2000-07-12
NO326479B1 (no) 2008-12-15
PT1017381E (pt) 2005-06-30
NO20000989D0 (no) 2000-02-28
US5990162A (en) 1999-11-23
ES2235355T3 (es) 2005-07-01
HK1029278A1 (en) 2001-03-30
NO20000989L (no) 2000-04-03
NZ502983A (en) 2001-08-31
CZ2000741A3 (cs) 2000-09-13
JP3660587B2 (ja) 2005-06-15

Similar Documents

Publication Publication Date Title
AU737086B2 (en) Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome
Mitler et al. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam
Cole Therapeutic efficacy of antidepressant drugs: a review
JP2008519847A (ja) 運動障害の治療方法
US20100227916A1 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
CA3195856A1 (en) Treatment methods using ghb
EP0552205B1 (en) New medical use for a certain indole derivative and pharmaceutical composition containing it
Ziegler et al. Effect of midazolam on sleep.
HK1029278B (en) Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome
Dressing et al. The effects of biperiden on nap sleep after sleep deprivation in depressed patients
JP2025512495A (ja) 発作性障害の治療
WO1999056747A1 (en) Compositions and methods for treating particular chemical addictions and mental illnesses
DRIPPS SELECTIVE UTILIZATION OF BARBITURATES: As Illustrated by a Study of Butabarbital Sodium (NNR)
Frey et al. Nonorganic lnsomnia in Generalized Anxiety Disorder
Derman et al. Sleep Disorders and their Psychiatric Significance
JPH03246225A (ja) メランコリーうつ病の治療法
Lehman Neurologic complications of alcoholism
Linford Rees The treatment of anxiety states by drugs and other means

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)